Health outcomes after stopping long-term mepolizumab in severe eosinophilic asthma: COMET
| Autor: | Marc Humbert, Elisabeth H. Bel, Mark C. Liu, Norihiro Kaneko, Oliver Kornmann, Steven G. Smith, Wendy C. Moore, Neil Martin, Steven W. Yancey, Robert G. Price |
|---|---|
| Přispěvatelé: | Pulmonary medicine |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | ERJ Open Research article-version (VoR) Version of Record Liu, M C, Bel, E H, Kornmann, O, Moore, W C, Kaneko, N, Smith, S G, Martin, N, Price, R G, Yancey, S W & Humbert, M 2022, ' Health outcomes after stopping long-term mepolizumab in severe eosinophilic asthma : COMET ', ERJ Open Research, vol. 8, no. 1, 00419-2021 . https://doi.org/10.1183/23120541.00419-2021 ERJ Open Research, 8(1):00419-2021. BMJ Publishing Group |
| ISSN: | 2312-0541 2044-6055 |
| DOI: | 10.1183/23120541.00419-2021 |
| Popis: | Asthma worsening and symptom control are clinically important health outcomes in patients with severe eosinophilic asthma. This analysis of COMET evaluated whether stopping versus continuing long-term mepolizumab therapy impacted these outcomes. Patients with severe eosinophilic asthma with ≥3 years continuous mepolizumab treatment (via COLUMBA (NCT01691859) or COSMEX (NCT02135692) open-label studies) were eligible to enter COMET (NCT02555371), a randomised, double-blind, placebo-controlled study. Patients were randomised 1:1 to continue mepolizumab 100 mg subcutaneous every 4 weeks or to stop mepolizumab, plus standard of care asthma treatment. Patients could switch to open-label mepolizumab following an exacerbation. Health outcome endpoints included time to first asthma worsening (composite endpoint: rescue use, symptoms, awakening at night and morning peak expiratory flow (PEF)), patient and clinician assessed global rating of asthma severity and overall perception of response to therapy, and unscheduled healthcare resource utilisation. Patients who stopped mepolizumab showed increased risk of and shorter time to first asthma worsening compared with those who continued mepolizumab (hazard ratio (HR) 1.71; 95% CI 1.17–2.52; p=0.006), including reduced asthma control (increased risk of first worsening in rescue use (HR 1.36; 95% CI 1.00–1.84; p=0.047) and morning PEF (HR 1.77; 95% CI 1.21–2.59; p=0.003). There was a higher probability of any unscheduled healthcare resource use (HR 1.81; 95% CI 1.31–2.49; p The COMET study investigated whether stopping long-term mepolizumab had an impact on health outcomes in patients with severe eosinophilic asthma; data suggest those who continue long-term mepolizumab treatment sustain clinically important improvements https://bit.ly/3A0bvwu |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|